A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: A randomized, double-blind study

Kaasa, Stein; Kvaløy, Stein; Dicato, Mario; Ries, F.; Huys, J; Royer, Eric; Carruthers, Linda

doi:10.1016/0277-5379(90)90227-k

Cited by 78 publications

(22 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Granisetron was superior to the combination of prednisolone plus metopimazine in the treatment of acute nausea and vomiting during the first cycle of chemotherapy. CR on day 1 was obtained in 68.8% of the patients treated with granisetron in accordance with the results in other trials investigating a 5-hydroxytryptamine 3 (5-HT 3 ) antagonist (Bonneterre et al, 1990;Kaasa et al, 1990;Marty, 1990;Jones et al, 1991;Marschner et al, 1991;Warr et al, 1991;Italian Group for Antimetic Research, 1995b). When the trial was initiated granisetron was available in Denmark for intravenous use only.…”

Section: Discussionsupporting

confidence: 87%

Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy

Sigsgaard

Herrstedt

et al. 1999

Br J Cancer

View full text Add to dashboard Cite

Summary This randomized, double-blind, double-dummy parallel study compared the anti-emetic efficacy and tolerability of the serotonin antagonist granisetron with prednisolone plus the dopamine D 2 antagonist metopimazine during nine cycles of moderately emetogenic chemotherapy. Chemotherapy naive women with stage I or II breast cancer scheduled to intravenous cyclophosphamide, fluorouracil and methotrexate or cyclophosphamide, epirubicin and fluorouracil every 3 weeks were included. Patients received a single intravenous dose of granisetron 3 mg or a 3-day oral treatment with prednisolone 25 mg once a day plus metopimazine 30 mg four times a day. A total of 223 women were enrolled and 218 patients (97.8%) were evaluable for efficacy. Granisetron (n = 109) was superior to prednisolone plus metopimazine (n = 109) in the prophylaxis of acute nausea and vomiting during the first cycle of chemotherapy (P < 0.001) and prednisolone plus metopimazine was superior on days 2-5 (P = 0.002). Overall, granisetron was superior on days 1-5 (P = 0.009). The median number of cycles completed with granisetron was five (95% confidence interval 4-6) compared with two (95% confidence interval 2-2) for prednisolone plus metopimazine (P = 0.0019). Constipation and rash were reported more frequently with granisetron (P < 0.001 and P = 0.043 respectively) and palpitations more frequently with prednisolone plus metopimazine (P = 0.015). In conclusion, the number of cycles completed with granisetron was significantly higher than the number completed with prednisolone plus metopimazine, but the anti-emetic efficacy of both treatments declined during multiple cycles of moderately emetogenic chemotherapy.

show abstract

Section: Discussionsupporting

confidence: 87%

Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy

Sigsgaard

Herrstedt

et al. 1999

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…In randomised studies it has been proven superior to both placebo (Cubeddu et al, 1990) and high dose metoclopramide (Marty et al, 1990) in controlling cisplatin induced emesis. In non-cisplatin containing chemotherapy regimens it has been shown superior to metoclopramide in four randomised studies (Schmoll, 1989;Kaasa et al, 1990).Vomiting after most chemotherapeutic agents tends to start within a couple of hours of treatment. The onset of vomiting after carboplatin, however, is often delayed for 6-1O h (Calvert et al, 1982) and there is no previous study of the effect of ondansetron on carboplatin induced vomiting.…”

mentioning

confidence: 99%

mentioning

confidence: 99%

Reduction of carboplatin induced emesis by ondansetron

Harvey

Evans²,

Mitchell³

et al. 1991

Br J Cancer

View full text Add to dashboard Cite

al., 1988;Hesketh et al., 1989;Einhorn et al., 1990). In randomised studies it has been proven superior to both placebo (Cubeddu et al., 1990) and high dose metoclopramide (Marty et al., 1990) in controlling cisplatin induced emesis. In non-cisplatin containing chemotherapy regimens it has been shown superior to metoclopramide in four randomised studies (Schmoll, 1989;Kaasa et al., 1990).Vomiting after most chemotherapeutic agents tends to start within a couple of hours of treatment. The onset of vomiting after carboplatin, however, is often delayed for 6-1O h (Calvert et al., 1982) and there is no previous study of the effect of ondansetron on carboplatin induced vomiting. This paper reports our initial experience with ondansetron in patients treated with carboplatin, who had proven refractory to a previous aggressive antiemetic regimen. Patients and methods PatientsAdult patients receiving carboplatin chemotherapy were eligible for treatment with ondansetron if they had vomited three times or more in the first 24 h of the previous course of chemotherapy. However, patients were excluded if they had a severe concurrent illness other than neoplasia, had hepatic dysfunction other than due to metastases or were receiving any other antiemetic medication, including benzodiazepines.Twenty-three women with ovarian cancer receiving carboplatin alone (300-400 mg m-2) and two men with testicular germ cell tumours receiving carboplatin (300 mg m2) with

show abstract

“…In cyclophosphamide and antracycline combination regimens, OND used as single antiemetic drug has proved to be superior to MCP (6,7) in treating acute nausea and emesis, and comparable to MCP combination regimens (8) and dexamethasone used as monotherapy respectively (9). In breast cancer patients receiving moderately emetogenic CT, the combination of OND and dexamethasone is significantly better than MCP and dexamethasone in the control of acute and delayed nausea and emesis over 6 courses of treatment (10).…”

mentioning

confidence: 99%

Antiemetic Efficacy of Ondansetron and Metoclopramide, Both Combined with Corticosteroid, in Malignant Lymphoma Patients Receiving Non-Cisplatin Chemotherapy

Jørgensen

Victor

1996

Acta Oncologica

View full text Add to dashboard Cite

A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: A randomized, double-blind study

Cited by 78 publications

References 10 publications

Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy

Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy

Reduction of carboplatin induced emesis by ondansetron

Antiemetic Efficacy of Ondansetron and Metoclopramide, Both Combined with Corticosteroid, in Malignant Lymphoma Patients Receiving Non-Cisplatin Chemotherapy

Contact Info

Product

Resources

About